PDCD1 and Hodgkins lymphoma: Variable expression of PD-1 and TIGIT was observed on CD3+ T cells in patients with Hodgkin lymphoma, suggesting that TIGIT blockade alone or in combination with other drugs might be used as a potential therapeutic target.